BACKGROUND: Insulin resistance is a frequent feature of chronic hepatitis C. Whether insulin resistance could be the cause or consequence of steatosis and fibrosis is unknown. The ability of HCV genotype 3 to promote steatosis by itself provides an unique opportunity to answer this question. AIMS: The aim of the present study was to assess the relationships between insulin resistance, steatosis, and fibrosis according to genotype in 141 non-diabetic patients with biopsy proven non-cirrhotic chronic hepatitis C. METHODS: All patients had fasting serum glycaemia and insulinaemia measurements. Insulin resistance was evaluated using the homeostasis model assessment (HOMA IR) method. Liver steatosis was determined according to hepatitis C virus genotype (1 or 3). Logistic regression and multivariate regression analysis were used to identify variables independently associated with insulin resistance, fatty liver, and fibrosis. RESULTS: Although steatosis and fibrosis were more severe in genotype 3 patients, median HOMA IR was significantly higher in patients with genotype 1 related steatosis than in those with genotype 3 related steatosis (2.1 v 1; p = 0.001). Independent risk factors for steatosis were insulin resistance in genotype 1 patients (p = 0.001) and viral load in genotype 3 patients (p = 0.003). Among genotype 1 patients, independent parameters associated with insulin resistance were age (p = 0.04) and steatosis (p = 0.004). Steatosis was associated with more severe fibrosis whatever the genotype (p = 0.002). Among genotype 1 patients, although there was a significant relationship between circulating insulin level and fibrosis stage (p = 0.006), only steatosis and inflammatory score were independently associated with fibrosis. CONCLUSION: This study shows that insulin resistance is the cause rather than the consequence of steatosis and fibrosis in genotype 1 patients and that increased circulating insulin is a risk factor for fibrosis through insulin resistance induced steatosis.
BACKGROUND:Insulin resistance is a frequent feature of chronic hepatitis C. Whether insulin resistance could be the cause or consequence of steatosis and fibrosis is unknown. The ability of HCV genotype 3 to promote steatosis by itself provides an unique opportunity to answer this question. AIMS: The aim of the present study was to assess the relationships between insulin resistance, steatosis, and fibrosis according to genotype in 141 non-diabeticpatients with biopsy proven non-cirrhotic chronic hepatitis C. METHODS: All patients had fasting serum glycaemia and insulinaemia measurements. Insulin resistance was evaluated using the homeostasis model assessment (HOMA IR) method. Liver steatosis was determined according to hepatitis C virus genotype (1 or 3). Logistic regression and multivariate regression analysis were used to identify variables independently associated with insulin resistance, fatty liver, and fibrosis. RESULTS: Although steatosis and fibrosis were more severe in genotype 3 patients, median HOMA IR was significantly higher in patients with genotype 1 related steatosis than in those with genotype 3 related steatosis (2.1 v 1; p = 0.001). Independent risk factors for steatosis were insulin resistance in genotype 1 patients (p = 0.001) and viral load in genotype 3 patients (p = 0.003). Among genotype 1 patients, independent parameters associated with insulin resistance were age (p = 0.04) and steatosis (p = 0.004). Steatosis was associated with more severe fibrosis whatever the genotype (p = 0.002). Among genotype 1 patients, although there was a significant relationship between circulating insulin level and fibrosis stage (p = 0.006), only steatosis and inflammatory score were independently associated with fibrosis. CONCLUSION: This study shows that insulin resistance is the cause rather than the consequence of steatosis and fibrosis in genotype 1 patients and that increased circulating insulin is a risk factor for fibrosis through insulin resistance induced steatosis.
Authors: Brent A Neuschwander-Tetri; Elizabeth M Brunt; Kent R Wehmeier; Dana Oliver; Bruce R Bacon Journal: Hepatology Date: 2003-10 Impact factor: 17.425
Authors: Jason M Hui; Archana Sud; Geoffrey C Farrell; Priyanka Bandara; Karen Byth; James G Kench; Geoffrey W McCaughan; Jacob George Journal: Gastroenterology Date: 2003-12 Impact factor: 22.682
Authors: Kitt Falk Petersen; Douglas Befroy; Sylvie Dufour; James Dziura; Charlotte Ariyan; Douglas L Rothman; Loretta DiPietro; Gary W Cline; Gerald I Shulman Journal: Science Date: 2003-05-16 Impact factor: 47.728
Authors: Marc G Ghany; David E Kleiner; Harvey Alter; Edward Doo; Farooq Khokar; Kittichai Promrat; David Herion; Yoon Park; T Jake Liang; Jay H Hoofnagle Journal: Gastroenterology Date: 2003-01 Impact factor: 22.682
Authors: Jie An; Deborah M Muoio; Masakazu Shiota; Yuka Fujimoto; Gary W Cline; Gerald I Shulman; Timothy R Koves; Robert Stevens; David Millington; Christopher B Newgard Journal: Nat Med Date: 2004-02-08 Impact factor: 53.440
Authors: Hongfa Zhu; Henry C Bodenheimer; David J Clain; Albert D Min; Neil D Theise Journal: World J Gastroenterol Date: 2010-10-28 Impact factor: 5.742
Authors: Cindy X Cai; Hema Buddha; Shobha Castelino-Prabhu; Zhiwei Zhang; Robert S Britton; Bruce R Bacon; Brent A Neuschwander-Tetri Journal: Dig Dis Sci Date: 2017-02-13 Impact factor: 3.199